The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse

Author

  • Mark Levis
  • Farhad Ravandi
  • Eunice S. Wang
  • Maria R. Baer
  • Alexander Perl
  • Steven Coutre
  • Harry Erba
  • Robert K. Stuart
  • Michele Baccarani
  • Larry D. Cripe
  • Martin S. Tallman
  • Giovanna Meloni
  • Lucy A. Godley
  • Amelia A. Langston
  • Sergio Amadori
  • Ian D. Lewis
  • Arnon Nagler
  • Richard Stone
  • Karen Yee
  • Anjali Advani
  • Dan Douer
  • Wieslaw W. Jedrzejczak
  • Gunnar Juliusson
  • Mark R. Litzow
  • Stephen Petersdorf
  • Miguel Sanz
  • Hagop M. Kantarjian
  • Takashi Sato
  • Lothar Tremmel
  • Debra M. Bensen-Kennedy
  • Donald Small
  • B. Douglas Smith

Department/s

Publishing year

2009

Language

English

Pages

325-326

Publication/Series

Blood

Volume

114

Issue

22

Document type

Conference paper: abstract

Publisher

American Society of Hematology

Topic

  • Hematology

Conference name

51st Annual Meeting of the American-Society-of-Hematology

Conference date

2009-12-05 - 2009-12-08

Status

Published

ISBN/ISSN/Other

  • ISSN: 1528-0020